NCT03817411 is a Phase 2 clinical trial of Telatinib in Gastric Cancer, sponsored by Taizhou EOC Pharma Co., Ltd..

Who is sponsoring NCT03817411?

NCT03817411 is sponsored by Taizhou EOC Pharma Co., Ltd..

What drugs are being tested in NCT03817411?

Interventions in NCT03817411: Telatinib, Capecitabine, Oxaliplatin, Placebos.

What condition does NCT03817411 study?

NCT03817411 studies Gastric Cancer.

Is NCT03817411 still recruiting?

NCT03817411 is currently status unknown. Last updated 7 May 2019.

Last reviewed 2019-05-07 · How we verify

NCT03817411

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Telatinib in Combination With Capecitabine/ Oxaliplatin in 1st Line Gastric or GEJ Cancer

Status unknown Phase 2 Last updated 7 May 2019

What this trial tests

Phase 2 trial testing Telatinib in Gastric Cancer in 90 participants. Status unknown.

Timeline

25 January 2019

Primary endpoint
30 March 2020

25 January 2021

Quick facts

Lead sponsor	Taizhou EOC Pharma Co., Ltd.
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	90
Start date	25 January 2019
Primary completion	30 March 2020
Estimated completion	25 January 2021
Sites	1 location across China

Drugs / interventions tested

Telatinib
Capecitabine (capecitabine) — full drug profile →
Oxaliplatin (Oxaliplatin) — full drug profile →
Placebos — full drug profile →

Conditions studied

Gastric Cancer — all drugs for Gastric Cancer →

Sponsor

Taizhou EOC Pharma Co., Ltd. — full company profile →

Who can join

Adults 18 to 75, any sex, with Gastric Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the trial is to compare the combination regimen of Telatinib and Capecitabine and Oxaliplatin vs. Capecitabine and Oxaplatin to explore superiority of the Telatinib combination in terms of progression-free survival (PFS) in patients previously untreated for advanced HER2 negative advanced gastric or Gastroesophageal Junction adenocarcinoma.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Angiogenic signaling pathways and anti-angiogenic therapy for cancer.
Liu ZL, Chen HH, Zheng LL, Sun LP, et al · · 2023 · cited 808× · PMID 37169756 · DOI 10.1038/s41392-023-01460-1
Tyrosine Kinase Receptors in Oncology.
Esteban-Villarrubia J, Soto-Castillo JJ, Pozas J, San Román-Gil M, et al · · 2020 · cited 72× · PMID 33198314 · DOI 10.3390/ijms21228529
Angiogenesis and targeted therapy in the tumour microenvironment: From basic to clinical practice.
Yang S, Fang Y, Ma Y, Wang F, et al · · 2025 · cited 22× · PMID 40268524 · DOI 10.1002/ctm2.70313
Molecular-targeted therapy toward precision medicine for gastrointestinal caner: Current progress and challenges.
Matsuoka T, Yashiro M. · · 2021 · cited 7× · PMID 34040699 · DOI 10.4251/wjgo.v13.i5.366
Recent Advancements in Lung Cancer Metastasis Prevention Based on Nanostrategies.
Xu F, Liu Y, Que Z, Luo B, et al · · 2025 · cited 3× · PMID 40135802 · DOI 10.1002/advs.202409293

Verify or expand the search:

Other trials of Telatinib

Trials testing the same drug.

NCT04798781 — Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Jun · Phase 2 · completed

Other recruiting trials for Gastric Cancer

Currently open trials in the same condition.

NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting

Other Taizhou EOC Pharma Co., Ltd. trials

Trials by the same sponsor.

NCT03600090 — Phase I Study of EOC202 Plus Paclitaxel in Chinese Patients With Metastatic Breast Cancer · Phase 1 · completed
NCT03583125 — Study of EOC317 in Chinese Patients With Advanced Solid Tumors · Phase 1 · unknown
NCT03175497 — Telatinib Safety and Pharmacokinetics Study in China Patients With Advanced Solid Tumors · Phase 1 · completed
NCT02833155 — Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03817411 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Taizhou EOC Pharma Co., Ltd.
Last refreshed: 7 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03817411.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing